Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.

Ruiter R, Visser LE, van Herk-Sukel MP, Geelhoed-Duijvestijn PH, de Bie S, Straus SM, Mol PG, Romio SA, Herings RM, Stricker BH.

Drug Saf. 2012 Jun 1;35(6):471-80. doi: 10.2165/11596950-000000000-00000.

PMID:
22540371
2.

Comment on: prescribing of rosiglitazone and pioglitazone following safety signals analysis of trends in dispensing patterns in The Netherlands from 1998 to 2008.

Carracedo-Martínez E.

Drug Saf. 2014 Dec;37(12):1069-70. doi: 10.1007/s40264-014-0227-y. No abstract available.

PMID:
25249047
4.

Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.

Niyomnaitham S, Page A, La Caze A, Whitfield K, Smith AJ.

BMC Health Serv Res. 2014 Apr 4;14:151. doi: 10.1186/1472-6963-14-151.

5.

Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone.

Leal I, Romio SA, Schuemie M, Oteri A, Sturkenboom M, Trifirò G.

Br J Clin Pharmacol. 2013 Mar;75(3):861-8. doi: 10.1111/j.1365-2125.2012.04401.x.

6.

Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.

Ahuja V, Sohn MW, Birge JR, Syverson C, Budiman-Mak E, Emanuele N, Cooper JM, Huang ES.

J Manag Care Spec Pharm. 2015 Dec;21(12):1214-34.

7.

A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.

Mol PG, Straus SM, Piening S, de Vries JT, de Graeff PA, Haaijer-Ruskamp FM.

Drug Saf. 2010 Jun 1;33(6):463-74. doi: 10.2165/11532840-000000000-00000.

PMID:
20486729
8.

Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.

Starner CI, Schafer JA, Heaton AH, Gleason PP.

J Manag Care Pharm. 2008 Jul-Aug;14(6):523-31.

9.

Inconsistencies among European Union pharmaceutical regulator safety communications: a cross-country comparison.

Zeitoun JD, Lefèvre JH, Downing N, Bergeron H, Ross JS.

PLoS One. 2014 Oct 21;9(10):e109100. doi: 10.1371/journal.pone.0109100. eCollection 2014.

10.

The impact of direct healthcare professional communication on prescribing practice in the UK hospital setting: an interrupted time series analysis.

Thomas SK, Hodson J, McIlroy G, Dhami A, Coleman JJ.

Drug Saf. 2013 Jul;36(7):557-64. doi: 10.1007/s40264-013-0057-3.

PMID:
23657825
11.

Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.

Hall GC, Smith HT, Curtis B, McMahon AD.

Int J Clin Pract. 2011 May;65(5):586-91. doi: 10.1111/j.1742-1241.2011.02648.x.

PMID:
21489082
12.

Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone.

Stewart KA, Natzke BM, Williams T, Granger E, Casscells SW, Croghan TW.

Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1048-52. doi: 10.1002/pds.1819.

PMID:
19655338
13.

Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan.

Hsu JC, Cheng CL, Ross-Degnan D, Wagner AK, Zhang F, Kao Yang YH, Liu LL, Tai HY, Chen KH, Yang PW, Lu CY.

Pharmacoepidemiol Drug Saf. 2015 Oct;24(10):1026-35. doi: 10.1002/pds.3834. Epub 2015 Aug 6.

PMID:
26251229
14.

Impact of the sitagliptin alert on prescription of oral antihyperglycemic drugs in Japan.

Sato D, Sato Y, Masuda S, Kimura H.

Int J Clin Pharm. 2012 Dec;34(6):917-24. doi: 10.1007/s11096-012-9694-3. Epub 2012 Sep 1.

PMID:
22941471
15.

Impact of rosiglitazone safety alerts on oral antidiabetic sales trends: a countrywide study in Portugal.

Herdeiro MT, Soares S, Silva T, Roque F, Figueiras A.

Fundam Clin Pharmacol. 2016 Oct;30(5):440-9. doi: 10.1111/fcp.12207. Epub 2016 Jul 6.

PMID:
27259384
16.

Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004-2013.

Clemens KK, Liu K, Shariff S, Schernthaner G, Tangri N, Garg AX.

Diabetes Obes Metab. 2016 Jun;18(6):607-14. doi: 10.1111/dom.12658. Epub 2016 Apr 12.

PMID:
26939711
17.

Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone.

Mendes D, Alves C, Batel-Marques F.

Pharmacoepidemiol Drug Saf. 2015 Dec;24(12):1259-70. doi: 10.1002/pds.3874. Epub 2015 Sep 16.

PMID:
26376779
18.

Changes in glitazone use among office-based physicians in the U.S., 2003-2009.

Cohen A, Rabbani A, Shah N, Alexander GC.

Diabetes Care. 2010 Apr;33(4):823-5. doi: 10.2337/dc09-1834. Epub 2010 Jan 26.

19.

Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.

Jain R, Mullins CD, Lee H, Wong W.

Res Social Adm Pharm. 2012 Jan-Feb;8(1):47-59. doi: 10.1016/j.sapharm.2010.12.003. Epub 2011 Jul 6.

PMID:
21733760
20.

Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.

Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA.

Drug Saf. 2009;32(5):409-18. doi: 10.2165/00002018-200932050-00004.

PMID:
19419235

Supplemental Content

Support Center